Axitinib implant - Alcon
Alternative Names: AR-14034; AR-14034 SRLatest Information Update: 27 Dec 2023
At a glance
- Originator Aerie Pharmaceuticals
- Developer Aerie Pharmaceuticals; Alcon
- Class Antineoplastics; Benzamides; Eye disorder therapies; Imidazoles; Indazoles; Pyridines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor beta receptor antagonists; Protein tyrosine kinase inhibitors; Proto-oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Age-related macular degeneration
- Preclinical Diabetic macular oedema; Wet age-related macular degeneration
Most Recent Events
- 27 Dec 2023 Chemical structure information added
- 06 Dec 2023 Phase-I/II clinical trials in Age-related macular degeneration in USA (Intravitreous) (NCT05769153)
- 17 Mar 2023 Aerie Pharmaceuticals in collaboration with Alcon Research plans a phase I/II NOVA-1 trial in neovascular Age-related macular degeneration in June 2023 (Intravitreal, Implant) (NCT05769153)